Has Matthew Schwartz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $169,017 in general payments to Matthew Schwartz, MD across 440 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Schwartz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Schwartz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Schwartz, MD

Radiation Oncology · Henderson, NVNPI 1053320424

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $132,317 of the $169,017 with a category attached, or 78.3%. Regeneron Healthcare Solutions, Inc. accounts for 84.8% of it on its own, with 49 other manufacturers making up the rest. Among radiation oncology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$169,017in general payments, 2019–2025

Across 440 payments — averaging $384.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron Healthcare Solutions, Inc.$143K
Sanofi$11K
Regeneron$8K
Daiichi Sankyo Inc.$1K
Bayer$984
AstraZeneca$837
plus $4K from 44 others

What the payments were for

Consulting fees$21,31113%
Speaking & faculty fees$132,31778%
Travel & lodging$5,9344%
Food & beverage$9,4556%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron Healthcare Solutions, Inc.	144	$143,345
Sanofi	10	$11,031
Regeneron	7	$7,827
Daiichi Sankyo Inc.	94	$1,195
Bayer	4	$984
AstraZeneca	16	$837
Novartis	26	$523
Exelixis Inc.	12	$314
Johnson & Johnson	10	$222
Genentech USA, Inc.	10	$221
Amgen	12	$180
Sobi, Inc	7	$175
Merck	7	$161
Beigene USA, Inc.	5	$155
Incyte Corporation	6	$152
Bristol Myers Squibb	6	$139
Icotec Medical Inc.	1	$124
Monteris Medical Corporation	2	$122
Karyopharm Therapeutics Inc.	3	$102
Takeda Pharmaceuticals U.S.A., Inc.	4	$96
EMD Serono, Inc.	5	$94
Gilead	3	$87
Novocure Inc.	4	$82
Astellas Pharma US Inc	3	$58
Stemline Therapeutics Inc.	3	$56
Sumitomo Pharma America, Inc.	3	$55
Eisai Inc.	3	$55
Genmab U.S., Inc.	2	$48
Lilly USA, LLC	3	$47
Coherus Oncology, Inc.	2	$46
Tempus AI, Inc	2	$45
Mirati Therapeutics, Inc.	2	$38
Boehringer Ingelheim	1	$33
Seagen Inc.	2	$32
Rigel Pharmaceuticals, Inc.	1	$31
Dendreon Pharmaceuticals LLC	1	$28
Alnylam Pharmaceuticals Inc.	1	$27
Azurity Pharmaceuticals, Inc.	1	$25
Avyxa Pharma, LLC	1	$24
Pharmacyclics LLC, An Abbvie Company	1	$23
Puma Biotechnology, Inc.	1	$22
GSK	1	$21
Jazz Pharmaceuticals Inc.	1	$20
Inogen, Inc.	1	$18
Sirtex Medical Inc	1	$18
Geron Corporation	1	$18
Octapharma USA, Inc.	1	$17
Pfizer	1	$16
Progenics Pharmaceuticals, Inc.	1	$15
AbbVie	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$169,017 in reported general payments places this provider in the 95th percentile of 47 radiation oncology providers in Nevada.

See all radiation oncology providers in Nevada →

Medicare billing

Part B allowed, 2024

$1,722,173

Medicare patients

388

Services billed

24,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Memantine Hcl	16	$373
Lidocaine Hcl ViscousLidocaine Hcl	12	$346
Tamsulosin Hcl	13	$189

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Henderson

Michael AndersonHenderson$36K
Paul TreadwellHenderson$108
Guy JonesReno$57K
Garrett GreenReno$37K
Jason KehrerReno$27K
Farzaneh FarzinLas Vegas$12K
Samual FrancisLas Vegas$10K
Ritchie StevensLas Vegas$9K
Anita PomerantzLas Vegas$9K
Michael SinopoliLas Vegas$5K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →